Patients Treated for SCID (1968-Present)



Status:Recruiting
Conditions:Infectious Disease, Ocular, Women's Studies
Therapuetic Areas:Immunology / Infectious Diseases, Ophthalmology, Reproductive
Healthy:No
Age Range:Any
Updated:11/23/2018
Start Date:May 2011
End Date:August 2019

Use our guide to learn which trials are right for you!

A Retrospective and Cross-Sectional Analysis of Patients Treated for SCID Since January 1,1968 (RDCRN PIDTC-6902)

People with Primary Immune Deficiency (PID) may develop severe, life-threatening infections
as a result of inherited defects in the genes that normally instruct blood-forming cells to
develop and to fight infections. PID diseases include Severe Combined Immune Deficiency
(SCID), leaky SCID, Omenn syndrome (OS), and Reticular Dysgenesis (RD). PIDs may be treated
by transplantation of bone marrow stem cells from a healthy person or, in some cases, by
enzyme replacement or by gene therapy. Patients with SCID were among the first to receive
bone marrow stem cell (also called hematopoietic cells) transplantation (HCT) more than 40
years ago, and HCT is the standard treatment today for this group of diseases. Since PID
diseases are rare, there are not enough patients at any single center to determine the full
range of causes, natural history, or best methods of treatment. For this research study many
PID centers across North America have organized into the Primary Immune Deficiency Treatment
Consortium (PIDTC) to pool their experience and study PIDs together. Researchers will collect
information on your general health, psychological and developmental health, and the current
status of your immune system to help better define future approaches to PID treatments.


Inclusion Criteria:

Strata A, B, and C (Part 1 - Retrospective Study)-

- Individuals with Severe Combined Immune Deficiency (SCID) diagnosis who:

--were treated at a location participating in this consortium from 1968 until present,
and

--are not enrolled in RDCRN PIDTC-6901 (ClinicalTrials.gov ID: NCT01186913).

- Subjects who received HCT/GT/ERT prior to the present date are eligible for the
retrospective study. The enrollment criteria for subjects who died prior to definitive
therapy are the same as for Strata A, B and C.

Stratum A, Typical SCID:

- Individuals who meet the following inclusion criteria and who received HCT are
eligible for enrollment into Stratum A of the study:

- Absence or very low number of T cells (CD3 T cells < 300/microliter), and no or
very low T cell function (< 10% of lower limit of normal) as measured by response
to phytohemagglutinin (PHA) or cells of maternal origin present.

- If maternal cells are present but the patient does not meet criteria for very low
T cell function as defined, the assigned reviewers for the potential subject, and
if necessary, the full PID‐SCID RP will review the laboratory report to determine
if criteria of maternal engraftment are met for Protocol 6902.

- Laboratory report of testing for maternal engraftment is required, for evaluation
by the PID‐SCID RP.

Stratum B, Leaky SCID, Omenn Syndrome, Reticular Dysgenesis:

Individuals who meet the following criteria are eligible for enrollment into Stratum B of
the study:

Leaky SCID-

- Maternal lymphocytes tested for and not detected and,

- Either one or both of the following (a,b):

a) < 50% of lower limit of normal T cell function (as measured by response to PHA OR <
50% of lower limit of normal T cell function as measured by response to CD3/CD28
antibody, b) Absent or < 30% lower limit of normal proliferative responses to candida
and tetanus toxoid antigens postvaccination or exposure,

- AND at least one of the following (a through e):

1. Reduced number of CD3 T cells,

2. > 80% of CD3+ or CD4 T cells are CD45RO+,

- AND/OR >80% of CD3+ or CD4+ T cells are,CD62L negative,

- AND/OR >50% of CD3+ or CD4+ T cells express HLA‐DR (at < 4 years of age),

- AND/OR are oligoclonal T cells. c) Hypomorphic mutation in IL2RG in a male, or
homozygous hypomorphic mutation or compound heterozygosity with at least one
hypomorphic mutation in an autosomal SCID‐causing gene.

d) Low TRECs and/or the percentage of CD4+/45RA+/CD31+ or CD4+/45RA+/CD62L+ cells is
below the lower limit of normal.

e) Functional testing in vitro supporting impaired, but not absent, activity of the
mutant protein,

- AND does not meet criteria for Omenn Syndrome,

- AND does not have known selective loss of lymphocytes, Ataxia‐ Telangiectasia, or
congenital heart defect associated with lymphopenia, unless a SCID genotype is
also present.

Omenn Syndrome (OS):

- Generalized skin rash,

- Maternal engraftment tested for and not detected,

- Absent or low (up to 30% of normal) T cell proliferation to antigens to which the
patient has been exposed.

- If the proliferation to antigen was not performed, but at least 4 of the following 10
supportive criteria, at least one of which must be among those marked with an asterisk
(*) are present, the patient is eligible: hepatomegaly; splenomegaly; lymphadenopathy;
elevated IgE; elevated absolute eosinophil count; *oligoclonal T cells measured by
CDR3 length or flow cytometry >80% of CD4+ T cells are CD45RO+ ;*proliferation to PHA
is reduced <50% of lower limit of normal or SI <30; *proliferative response in mixed
leukocyte reaction is reduced to increment cpm < 20% or SI <20; hypomorphic mutation
to SCID causing gene; low TRECs and/or percentage of CD 4+/ RA+/CD31+; or
CD4+/RA+/CD62L+ cells below the lower limit of normal.

Reticular Dysgenesis (RD):

- Absence or very low number of T cells (CD3 T cells <300/microliter),

- No or very low (<10% of lower limit of normal) T cell function (as measured by
response to phytohemagglutinin (PHA),

- Severe congenital neutropenia (absolute neutrophil count <200/microliter),

- AND at least one of the following:

- Sensorineural deafness and/or absence of granulopoiesis at bone marrow
examination and/or a deleterious AK2 mutation,

- absence of granulopoiesis on bone marrow examination; a pathogenic mutation in
the adenylate kinase 2 (AK2) gene identified.

Stratum C, SCID with Non-HCT Treatments:

-Individuals who meet the following criteria and were treated with PEG-ADA or gene therapy
with autologous modified cells are eligible for enrollment into Stratum C (SCID with
non-HCT treatments) of the study-

- Any SCID patient previously treated with a thymus transplant (includes intention to treat
with HCT, as well as PEG‐ADA ERT or gene therapy).

Strata A, B, and C (Part 2 - Cross-Sectional Study):

Patient inclusion criteria for the cross sectional study: Eligibility for Strata A, B and C
are the same as for the retrospective study except that all the patients in the
cross-sectional study are currently surviving and are at least 2 years post the most recent
class of therapy.

Exclusion Criteria:

Parts 1 and 2 - Retrospective and Cross-Sectional Studies -

- Lack of appropriate testing to rule out HIV infection after 1997 (p24 antigen or more
sensitive) or other cause of secondary immunodeficiency,

- Presence of DiGeorge syndrome,

- Most patients with other PIDs such as nucleoside phosphorylase deficiency, ZAP70
deficiency, CD40 ligand deficiency, NEMO deficiency, XLP, cartilage hair hypoplasia or
ataxia telangiectasia will not meet the inclusion criteria for Stratum A, B, or C
above; however, a patient with one of the above may meet the inclusion criteria for
Stratum B and if so will be included-

- MHC Class I and MHC Class II antigen deficiency are excluded,

- Metabolic conditions that imitate SCID or related disorders such as folate
transporter deficiency, severe zinc deficiency, transcobalamin deficiency.
We found this trial at
32
sites
Saint Louis, Missouri 63104
Principal Investigator: Alan Knutsen, MD
Phone: 314-268-2700
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
1720 2nd Ave S
Birmingham, Alabama 35233
(205) 934-4011 
Principal Investigator: Fredrick Goldman, MD
Phone: 205-939-5855
University of Alabama at Birmingham The University of Alabama at Birmingham (UAB) traces its roots...
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
3333 Burnet Avenue # Mlc3008
Cincinnati, Ohio 45229
 1-513-636-4200 
Principal Investigator: Sharat Chandra, MD
Phone: 513-636-5917
Cincinnati Children's Hospital Medical Center Patients and families from across the region and around the...
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Denver, Colorado 80218
Principal Investigator: Hesham Eissa, MD
Phone: 720-777-5179
?
mi
from
Denver, CO
Click here to add this to my saved trials
Durham, North Carolina 27710
(919) 684-8111
Principal Investigator: Rebecca Buckley, MD
Phone: 919-684-2922
Duke University Younger than most other prestigious U.S. research universities, Duke University consistently ranks among...
?
mi
from
Durham, NC
Click here to add this to my saved trials
4650 Sunset Blvd
Los Angeles, California 90027
 (323) 660-2450
Principal Investigator: Neena Kapoor, MD
Phone: 323-361-2217
Childrens Hospital Los Angeles Children's Hospital Los Angeles is a 501(c)(3) nonprofit hospital for pediatric...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Los Angeles, California 90095
310-825-4321
Principal Investigator: Theodore Moore, MD
Phone: 310-825-6708
University of California at Los Angeles The University of California, Los Angeles (UCLA) is an...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
262 Danny Thomas Pl
Memphis, Tennessee 38105
(901) 495-3300
Principal Investigator: Ewelina Mamcarz, MD
Phone: 901-595-8343
St. Jude Children's Research Hospital St. Jude is unlike any other pediatric treatment and research...
?
mi
from
Memphis, TN
Click here to add this to my saved trials
South 34th Street
Philadelphia, Pennsylvania 19104
 215-590-1000
Principal Investigator: Kathleen Sullivan, MD, PhD
Phone: 215-590-1697
Children's Hospital of Philadelphia Since its start in 1855 as the nation's first hospital devoted...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
3181 Southwest Sam Jackson Park Road
Portland, Oregon 97239
503 494-8311
Principal Investigator: Evan Shereck, MD
Phone: 503-494-0829
Oregon Health and Science University In 1887, the inaugural class of the University of Oregon...
?
mi
from
Portland, OR
Click here to add this to my saved trials
1500 E Medical Center Dr
Ann Arbor, Michigan 48109
(734) 936-4000
Principal Investigator: Mark Vander Lugt, MD
Phone: 737-936-9814
University of Michigan Health System The University of Michigan is home to one of the...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Atlanta, Georgia 30322
Principal Investigator: Shanmuganathan Chandrakasan, MD
Phone: 404-727-8877
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Bethesda, Maryland 20892
Principal Investigator: Harry Malech, MD
Phone: 301-480-6916
?
mi
from
Bethesda, MD
Click here to add this to my saved trials
Boston, Massachusetts 02115
Principal Investigator: Sung-Yun Pai, MD
Phone: 617-919-2508
?
mi
from
Boston, MA
Click here to add this to my saved trials
Calgary, Alberta
Principal Investigator: Nicola Wright, MD
Phone: 403-955-3035
?
mi
from
Calgary,
Click here to add this to my saved trials
225 E Chicago Ave
Chicago, Illinois 60611
(312) 227-4000
Principal Investigator: Sonali Chaudury, MD
Phone: 773-880-8153
Ann & Robert H. Lurie Children's Hospital of Chicago Ann & Robert H. Lurie Children
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Dallas, Texas 75390
Principal Investigator: Victor Aquino, MD
Phone: 214-648-8800
?
mi
from
Dallas, TX
Click here to add this to my saved trials
30 Prospect Ave
Hackensack, New Jersey 07601
(201) 996-2000
Principal Investigator: Alfred Gillio, MD
Phone: 201-996-5645
Hackensack University Medical Center Hackensack University Medical Center, part of the Hackensack University Health Network,...
?
mi
from
Hackensack, NJ
Click here to add this to my saved trials
6621 Fannin St
Houston, Texas 77030
(832) 824-1000
Principal Investigator: Lisa Forbes Satter, MD
Phone: 832-824-1339
Texas Children's Hospital Texas Children's Hospital, located in Houston, Texas, is a not-for-profit organization whose...
?
mi
from
Houston, TX
Click here to add this to my saved trials
Madison, Wisconsin 53705
Principal Investigator: Kenneth DeSantes, MD
Phone: 608-263-8563
?
mi
from
Madison, WI
Click here to add this to my saved trials
8701 W Watertown Plank Rd
Milwaukee, Wisconsin
(414) 955-8296
Principal Investigator: Julie An M Talano, MD
Phone: 414-456-4170
Medical College of Wisconsin The Medical College (MCW) of Wisconsin is a major national research...
?
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Minneapolis, Minnesota 55455
Principal Investigator: Angie Smith, MD
Phone: 612-626-2778
?
mi
from
Minneapolis, MN
Click here to add this to my saved trials
New Orleans, Louisiana 70118
Principal Investigator: Lolie Yu, MD
Phone: 504-896-9740
?
mi
from
New Orleans, LA
Click here to add this to my saved trials
1275 York Ave
New York, New York 10021
(212) 639-2000
Principal Investigator: Richard J O'Reilly, MD
Phone: 212-639-5957
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
?
mi
from
New York, NY
Click here to add this to my saved trials
Palo Alto, California 94304
Principal Investigator: Ami Shah, MD
Phone: 310-825-6708
?
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Saint Louis, Missouri 63110
Principal Investigator: Shalini Shenoy, MD
Phone: 314-454-6018
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Saint Petersburg, Florida 33701
Principal Investigator: Gauri Sunkersett, MD
Phone: 727-767-3513
?
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
Salt Lake City, Utah 84113
Principal Investigator: David Shyr, MD
Phone: 801-662-4736
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
San Antonio, Texas 78229
Principal Investigator: Troy Quigg, MD
Phone: 210-575-7348
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
San Francisco, California 94143
Principal Investigator: Christopher Dvorak, MD
Phone: 415-476-3875
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
Seattle, Washington 98109
Principal Investigator: Lauri Burroughs, MD
Phone: 206-667-2396
?
mi
from
Seattle, WA
Click here to add this to my saved trials
111 Michigan Ave NW
Washington, District of Columbia
(202) 476-5000
Principal Investigator: Blachy Saldaña, MD
Phone: 202-476-4561
Childrens National Medical Center As the nation’s children’s hospital, the mission of Children’s National Medical...
?
mi
from
Washington,
Click here to add this to my saved trials